| Size | Price | Stock | Qty |
|---|---|---|---|
| 250mg |
|
||
| 500mg |
|
||
| 1g |
|
||
| 5g |
|
||
| Other Sizes |
Purity: =99.15%
| Targets |
Ethyl Vanillin Glucoside does not have a defined pharmacological target in the context of drug development; it is primarily used as a flavor precursor. As a glycoside, it can be hydrolyzed by β-glucosidase enzymes to release ethyl vanillin, the active flavor compound. This property makes it a latent or slow-release flavoring agent.
|
|---|---|
| ln Vitro |
In vitro activity is assessed primarily through enzymatic hydrolysis assays rather than traditional pharmacological activity measurements. The compound serves as a substrate for β-glucosidase or related glycosidase enzymes, which cleave the glycosidic bond to release ethyl vanillin. Hydrolysis kinetics can be monitored by quantifying the release of ethyl vanillin over time using HPLC or spectrophotometric methods.
|
| ln Vivo |
In vivo, the compound acts as a prodrug or flavor precursor; upon ingestion, glycosidases in the digestive tract or oral microbiota hydrolyze the glucoside bond, releasing ethyl vanillin. The released ethyl vanillin then exerts its flavor and sensory effects. Systemic pharmacological activity is not expected as the compound is designed for flavor applications rather than therapeutic use.
|
| Enzyme Assay |
The typical cell-free assay involves incubation of Ethyl Vanillin Glucoside with β-glucosidase or glucoamylase enzymes in buffered solution at appropriate pH and temperature. The reaction is terminated at various time points, and the released ethyl vanillin is extracted and quantified by HPLC-UV or mass spectrometry. Kinetic parameters such as Km and Vmax can be determined from substrate concentration-response curves.
|
| Cell Assay |
Cellular assays are generally not applicable for this compound as it is a flavoring agent rather than a drug. However, cell-based models expressing β-glucosidase could be used to study cellular uptake and hydrolysis. In such systems, cells are incubated with the compound, and intracellular and extracellular ethyl vanillin levels are measured to assess glycoside hydrolysis and permeability.
|
| Animal Protocol |
Animal studies are not standard for this food additive. In hypothetical pharmacokinetic or metabolism studies, rodents could be administered Ethyl Vanillin Glucoside orally, with blood and tissue samples collected at various time points. Ethyl vanillin and its metabolites would be quantified by LC-MS/MS to assess the rate and extent of glycoside hydrolysis and systemic exposure to the released aglycone.
|
| ADME/Pharmacokinetics |
As a flavoring agent and food additive, systemic pharmacokinetic properties are not extensively characterized. The compound is expected to be hydrolyzed in the gastrointestinal tract by digestive enzymes or microbiota to release ethyl vanillin. The released ethyl vanillin is then absorbed, metabolized in the liver (primarily via conjugation), and excreted in urine. The glucoside moiety is metabolized via normal carbohydrate pathways.
|
| Toxicity/Toxicokinetics |
Ethyl Vanillin Glucoside is generally recognized as safe for use as a flavoring agent in food products. The compound is a mild and vanilla-tasting substance. It has been evaluated as a potential endocrine disrupting compound, though no significant toxicity has been reported at typical usage levels. Standard toxicological assessments for food additives would include acute, subchronic, and chronic toxicity studies, as well as genotoxicity and reproductive toxicity evaluations.
|
| Additional Infomation |
Ethyl Vanillin Glucoside (also known as ethylvanillin-D-glucose, 4-(β-D-glucosyl)-3-ethoxybenzaldehyde) is approximately three times as potent as vanillin as a flavoring agent and is used in the chocolate industry. It is a white solid at room temperature with molecular formula C15H20O8 and molecular weight 328.315. The compound is synthesized enzymatically using cyclodextrin glucanotransferase (CGTase) for transglycosylation. It is listed in the FDA's EAFUS database as a substance added to food.
|
| Molecular Formula |
C15H20O8
|
|---|---|
| Molecular Weight |
328.315
|
| Exact Mass |
328.116
|
| CAS # |
122397-96-0
|
| PubChem CID |
11163251
|
| Appearance |
Typically exists as white solid at room temperature
|
| Boiling Point |
593.6ºC at 760mmHg
|
| Flash Point |
213.4ºC
|
| Vapour Pressure |
6.15E-15mmHg at 25°C
|
| LogP |
-1.2
|
| Hydrogen Bond Donor Count |
4
|
| Hydrogen Bond Acceptor Count |
8
|
| Rotatable Bond Count |
6
|
| Heavy Atom Count |
23
|
| Complexity |
379
|
| Defined Atom Stereocenter Count |
5
|
| SMILES |
CCOC1C=C(C=O)C=CC=1O[C@@H]1O[C@H](CO)[C@@H](O)[C@H](O)[C@H]1O
|
| InChi Key |
SWESETWDPGZBCR-UXXRCYHCSA-N
|
| InChi Code |
InChI=1S/C15H20O8/c1-2-21-10-5-8(6-16)3-4-9(10)22-15-14(20)13(19)12(18)11(7-17)23-15/h3-6,11-15,17-20H,2,7H2,1H3/t11-,12-,13+,14-,15-/m1/s1
|
| Chemical Name |
3-ethoxy-4-[(2S,3R,4S,5S,6R)-3,4,5-trihydroxy-6-(hydroxymethyl)oxan-2-yl]oxybenzaldehyde
|
| Synonyms |
glucoethyl vanillin; Ethyl Vanillin Glucoside
|
| HS Tariff Code |
2934.99.9001
|
| Storage |
Powder -20°C 3 years 4°C 2 years In solvent -80°C 6 months -20°C 1 month |
| Shipping Condition |
Room temperature (This product is stable at ambient temperature for a few days during ordinary shipping and time spent in Customs)
|
| Solubility (In Vitro) |
May dissolve in DMSO (in most cases), if not, try other solvents such as H2O, Ethanol, or DMF with a minute amount of products to avoid loss of samples
|
|---|---|
| Solubility (In Vivo) |
Note: Listed below are some common formulations that may be used to formulate products with low water solubility (e.g. < 1 mg/mL), you may test these formulations using a minute amount of products to avoid loss of samples.
Injection Formulations
Injection Formulation 1: DMSO : Tween 80： Saline = 10 : 5 : 85 (i.e. 100 μL DMSO stock solution → 50 μL Tween 80 → 850 μL Saline)(e.g. IP/IV/IM/SC) *Preparation of saline: Dissolve 0.9 g of sodium chloride in 100 mL ddH ₂ O to obtain a clear solution. Injection Formulation 2: DMSO : PEG300 ：Tween 80 : Saline = 10 : 40 : 5 : 45 (i.e. 100 μL DMSO → 400 μLPEG300 → 50 μL Tween 80 → 450 μL Saline) Injection Formulation 3: DMSO : Corn oil = 10 : 90 (i.e. 100 μL DMSO → 900 μL Corn oil) Example: Take the Injection Formulation 3 (DMSO : Corn oil = 10 : 90) as an example, if 1 mL of 2.5 mg/mL working solution is to be prepared, you can take 100 μL 25 mg/mL DMSO stock solution and add to 900 μL corn oil, mix well to obtain a clear or suspension solution (2.5 mg/mL, ready for use in animals). View More
Injection Formulation 4: DMSO : 20% SBE-β-CD in saline = 10 : 90 [i.e. 100 μL DMSO → 900 μL (20% SBE-β-CD in saline)] Oral Formulations
Oral Formulation 1: Suspend in 0.5% CMC Na (carboxymethylcellulose sodium) Oral Formulation 2: Suspend in 0.5% Carboxymethyl cellulose Example: Take the Oral Formulation 1 (Suspend in 0.5% CMC Na) as an example, if 100 mL of 2.5 mg/mL working solution is to be prepared, you can first prepare 0.5% CMC Na solution by measuring 0.5 g CMC Na and dissolve it in 100 mL ddH2O to obtain a clear solution; then add 250 mg of the product to 100 mL 0.5% CMC Na solution, to make the suspension solution (2.5 mg/mL, ready for use in animals). View More
Oral Formulation 3: Dissolved in PEG400 (Please use freshly prepared in vivo formulations for optimal results.) |
| Preparing Stock Solutions | 1 mg | 5 mg | 10 mg | |
| 1 mM | 3.0458 mL | 15.2290 mL | 30.4581 mL | |
| 5 mM | 0.6092 mL | 3.0458 mL | 6.0916 mL | |
| 10 mM | 0.3046 mL | 1.5229 mL | 3.0458 mL |
*Note: Please select an appropriate solvent for the preparation of stock solution based on your experiment needs. For most products, DMSO can be used for preparing stock solutions (e.g. 5 mM, 10 mM, or 20 mM concentration); some products with high aqueous solubility may be dissolved in water directly. Solubility information is available at the above Solubility Data section. Once the stock solution is prepared, aliquot it to routine usage volumes and store at -20°C or -80°C. Avoid repeated freeze and thaw cycles.
Calculation results
Working concentration： mg/mL；
Method for preparing DMSO stock solution： mg drug pre-dissolved in μL DMSO (stock solution concentration mg/mL). Please contact us first if the concentration exceeds the DMSO solubility of the batch of drug.
Method for preparing in vivo formulation:：Take μL DMSO stock solution, next add μL PEG300, mix and clarify, next addμL Tween 80, mix and clarify, next add μL ddH2O，mix and clarify.
(1) Please be sure that the solution is clear before the addition of next solvent. Dissolution methods like vortex, ultrasound or warming and heat may be used to aid dissolving.
(2) Be sure to add the solvent(s) in order.
Products are for research use only; We do not sell to patients
Copyright 2020 InvivoChem LLC | All Rights Reserved
COA